Baltimore-Washington Financial Advisors’s Novartis NVS Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-391	Closed	-$35K	–	261
2015 Q1	$35K	Buy	391 +335	+598%	+$29.7K	0.01%	154
2014 Q4	$5K	Hold	56	–	–	﹤0.01%	229
2014 Q3	$5K	Sell	56 -642	-92%	-$51.9K	﹤0.01%	244
2014 Q2	$57K	Buy	+698	New	+$54.9K	0.02%	148
2014 Q1	–	Sell	-698	Closed	-$50K	–	274
2013 Q4	$50K	Hold	698	–	–	0.02%	162
2013 Q3	$48K	Buy	+698	New	+$46.2K	0.02%	121

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Baltimore-Washington Financial Advisors's NVS Position: Q2 2015 in Review

Baltimore-Washington Financial Advisors sold out of Novartis (NVS) in Q2 2015, closing a stake of 391 shares — an estimated $35K sold.

Baltimore-Washington Financial Advisors first reported a position in NVS in Q3 2013 and held it in 6 quarters. The position peaked at $57K in Q2 2014. 945 funds tracked by Wall St. Rank hold NVS as of Q2 2015.

Baltimore-Washington Financial Advisors reported no remaining Novartis position as of Q2 2015 after selling out during the quarter.
Baltimore-Washington Financial Advisors sold 391 Novartis shares in Q2 2015, an estimated $35K.
Baltimore-Washington Financial Advisors first reported a position in Novartis in Q3 2013 and held it in 6 quarters.
Baltimore-Washington Financial Advisors's Novartis position peaked at $57K in Q2 2014.
945 funds tracked by Wall St. Rank held Novartis as of Q2 2015.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q2 2015, filed 15 Jul 2015.